certepetide
certepetide: developed by 1 company · 2 clinical trials tracked.
certepetide evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could certepetide → LSTA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| LISATA THERAPEUTICS, INC. (LSTA) Cholangiocarcinoma; Pancreas Cancer | Phase 1/Phase 2 |
Clinical Trials (2)
A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)
Primary endpoint: Incidence of adverse events
A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)
Primary endpoint: Number of Subjects Experiencing Any Adverse Event
Frequently asked questions
Who is developing certepetide?
certepetide is being developed by LISATA THERAPEUTICS, INC..
How many clinical trials involve certepetide?
BioSniper tracks 2 clinical trials involving certepetide.